Search Results
B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager CC-93269 in Patients with RR Multiple Myeloma
Luciano Costa: CC-93269 Shows Clinical Activity in Previously Treated Myeloma
CARTITUDE-1: JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy for r/r mu...
Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
B-cell Maturation Antigen: A new biomarker for B-cell malignancies
Dr. Michael Chu on CC-93269, a bispecific T-cell engager (BiTE) targeting BCMA and CD3, shows...
BCMA: A new biomarker for multiple myeloma
BCMA-targeting therapies in myeloma
The benefits of bispecific antibodies for treating multiple myeloma
BCMA in Multiple Myeloma: Emerging Targeted Solutions
BCMA-Targeted Therapy in RRMM: Results From the DREAMM-1 Trial
CAR T-Cell Therapy Appears Promising for Heavily Pretreated Multiple Myeloma
